Published in Cancer Immunol Immunother on January 25, 2005
Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci U S A (2009) 1.78
The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J Interferon Cytokine Res (2010) 1.48
IRF9 is a key factor for eliciting the antiproliferative activity of IFN-alpha. J Immunother (2009) 1.07
Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha. Clin Cancer Res (2008) 1.02
Development of IFN-gamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells. Br J Cancer (2007) 0.93
Resistance to IFN-alpha-induced apoptosis is linked to a loss of STAT2. Mol Cancer Res (2010) 0.89
Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4⁺ and CD8⁺ T cells. Cancer Immunol Immunother (2011) 0.84
Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways. Oncotarget (2017) 0.75
Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma. PLoS One (2016) 0.75
STAT3 Inhibition Induces Apoptosis in Cancer Cells Independent of STAT1 or STAT2. J Mol Biochem (2013) 0.75
Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant (2007) 3.90
Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer (2008) 3.68
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87
Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol (2004) 2.55
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Pyoderma gangrenosum: a review. J Cutan Pathol (2003) 2.23
Responsiveness of the Neck Disability Index in patients with mechanical neck disorders. Spine J (2009) 1.94
Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants. Clin Cancer Res (2010) 1.76
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest (2002) 1.74
Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. Blood (2004) 1.73
Giant breast tumors: surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature. World J Surg Oncol (2008) 1.73
The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res (2007) 1.66
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol (2011) 1.65
Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res (2011) 1.61
Holidays, birthdays, and postponement of cancer death. JAMA (2004) 1.60
Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav Immun (2007) 1.59
Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol (2006) 1.58
20q11.1 amplification in giant-cell tumor of bone: Array CGH, FISH, and association with outcome. Genes Chromosomes Cancer (2006) 1.56
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res (2004) 1.55
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther (2009) 1.54
β-Adrenergic receptor mediated increases in activation and function of natural killer cells following repeated social disruption. Brain Behav Immun (2012) 1.50
The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol (2008) 1.49
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol (2007) 1.49
Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy. Cancer Immunol Immunother (2011) 1.47
Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.44
Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst (2004) 1.42
Chronic stress and susceptibility to skin cancer. J Natl Cancer Inst (2005) 1.41
Precancerous stem cells have the potential for both benign and malignant differentiation. PLoS One (2007) 1.36
Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther (2005) 1.33
Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol (2012) 1.33
Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res (2006) 1.32
The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer (2010) 1.27
Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma. Blood (2008) 1.26
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J Immunol (2011) 1.25
IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins. J Immunol (2007) 1.23
A psychological intervention reduces inflammatory markers by alleviating depressive symptoms: secondary analysis of a randomized controlled trial. Psychosom Med (2009) 1.22
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat (2008) 1.21
Review of S100A9 biology and its role in cancer. Biochim Biophys Acta (2012) 1.19
Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain Behav Immun (2006) 1.18
The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest (2003) 1.17
Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells. Clin Cancer Res (2007) 1.16
CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol (2005) 1.15
The Functional Movement Screen: a reliability study. J Orthop Sports Phys Ther (2012) 1.13
IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Cancer Res (2008) 1.11
Designing studies that would address the multilayered nature of health care. J Natl Cancer Inst Monogr (2010) 1.10
Senior adult oncology clinical practice guidelines in oncology. J Natl Compr Canc Netw (2005) 1.09
LONI visualization environment. J Digit Imaging (2006) 1.09
Case 18-2014: A man with a rash, myalgia, and weakness. N Engl J Med (2014) 1.09
Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis. Cancer Immunol Immunother (2008) 1.08
Melanoma, version 4.2014. J Natl Compr Canc Netw (2014) 1.07
Provider and patient perceptions about dental care during pregnancy. J Matern Fetal Neonatal Med (2008) 1.05
Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. Psychooncology (2012) 1.05
Studies with staggered starts: multiple baseline designs and group-randomized trials. Am J Public Health (2011) 1.05
Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat (2013) 1.04
Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res (2006) 1.04
Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cell Immunol (2011) 1.03
STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-alpha. Cancer Immunol Immunother (2007) 1.03
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.02
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res (2002) 1.02
Natural killer cells contribute to the lethality of a murine model of Escherichia coli infection. Surgery (2002) 1.02
Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res (2007) 1.02
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol (2009) 1.02
Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha. Clin Cancer Res (2008) 1.02
Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. J Clin Oncol (2012) 1.01
C3d and C4d deposition early after lung transplantation. J Heart Lung Transplant (2008) 1.01
Copy number gain and oncogenic activity of YWHAZ/14-3-3zeta in head and neck squamous cell carcinoma. Int J Cancer (2009) 1.01
Neuregulin growth factors and their ErbB receptors form a potential signaling network for schwannoma tumorigenesis. J Neuropathol Exp Neurol (2006) 1.00
Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Clin Cancer Res (2006) 1.00
Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci U S A (2010) 0.99
Prospective randomized clinical trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol (2006) 0.99
Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immunother (2014) 0.97
IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma. J Immunol (2004) 0.97
Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy. Clin Cancer Res (2010) 0.96
Stem cell-related markers in primary breast cancers and associated metastatic lesions. Mod Pathol (2012) 0.95
The immediate effects of thoracic spine and rib manipulation on subjects with primary complaints of shoulder pain. J Man Manip Ther (2009) 0.95
Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery (2012) 0.95
Advances in oncolytic virus therapy for glioma. Recent Pat CNS Drug Discov (2009) 0.94
Delayed emotional recovery after taxane-based chemotherapy. Cancer (2008) 0.93
Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobin-like receptors. J Surg Res (2007) 0.93
Fatigue and herpesvirus latency in women newly diagnosed with breast cancer. Brain Behav Immun (2011) 0.93
A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother (2011) 0.93
Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women. J Clin Oncol (2007) 0.93
Src homology 2-containing inositol 5'-phosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12. Cancer Res (2005) 0.93